Quent Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Quent Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31K	Hold	235	–	–	﹤0.01%	1423
2025 Q4	$1.73K	Buy	235 +4	+2%	+$24	﹤0.01%	1405
2025 Q3	$1.51K	Buy	+231	New	+$1.24K	﹤0.01%	1288
2025 Q2	–	Sell	-231	Closed	-$864	–	804
2025 Q1	$864	Sell	231 -2	-0.9%	-$17	﹤0.01%	1228
2024 Q4	$2.36K	Hold	233	–	–	﹤0.01%	1149
2024 Q3	$2.9K	Hold	233	–	–	﹤0.01%	1189
2024 Q2	$3.03K	Buy	+233	New	+$3.86K	﹤0.01%	1166
2023 Q2	–	Sell	-26	Closed	-$1.5K	–	1339
2023 Q1	$1.5K	Hold	26	–	–	﹤0.01%	1200
2022 Q4	$1.31K	Buy	26 +24	+1,200%	+$1.66K	﹤0.01%	1198
2022 Q3	$0	Hold	2	–	–	﹤0.01%	1246
2022 Q2	$0	Hold	2	–	–	﹤0.01%	1246
2022 Q1	$0	Buy	+2	New	+$249	﹤0.01%	1291

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Quent Capital's KPTI Position: Q1 2026 in Review

Quent Capital held its Karyopharm Therapeutics (KPTI) position steady in Q1 2026 at 235 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1423.

Quent Capital first reported a position in KPTI in Q1 2022 and has held it in 12 quarters since. The position peaked at $3.03K in Q2 2024. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Quent Capital held 235 shares of Karyopharm Therapeutics worth $1.31K as of Q1 2026.
Quent Capital left its Karyopharm Therapeutics share count unchanged in Q1 2026.
Karyopharm Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q1 2026, its #1423 holding.
Quent Capital first reported a position in Karyopharm Therapeutics in Q1 2022 and has held it in 12 quarters since.
Quent Capital's Karyopharm Therapeutics position peaked at $3.03K in Q2 2024.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.